IN2014DN09392A - - Google Patents

Download PDF

Info

Publication number
IN2014DN09392A
IN2014DN09392A IN9392DEN2014A IN2014DN09392A IN 2014DN09392 A IN2014DN09392 A IN 2014DN09392A IN 9392DEN2014 A IN9392DEN2014 A IN 9392DEN2014A IN 2014DN09392 A IN2014DN09392 A IN 2014DN09392A
Authority
IN
India
Prior art keywords
compounds
essentially pure
xxv
stimulating
formulas
Prior art date
Application number
Inventor
Walter A Shaw
Stephen W Burgess
Shengrong Li
David T Hickman
Maria Pilar Lopez-Deber
Original Assignee
Avanti Polar Lipids Inc
Ac Immune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avanti Polar Lipids Inc, Ac Immune Sa filed Critical Avanti Polar Lipids Inc
Publication of IN2014DN09392A publication Critical patent/IN2014DN09392A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06—Fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Abstract

Essentially pure compounds of the formulas (I) to (XXV) are provided. Compositions and methods for enhancing or stimulating an immune response are also provided. The compounds provided are advantageous in that the compounds are essentially pure and free from contaminants encountered when such compounds are purified from natural sources.
IN9392DEN2014 2012-04-12 2013-04-12 IN2014DN09392A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261623393P 2012-04-12 2012-04-12
US13/842,424 US9241988B2 (en) 2012-04-12 2013-03-15 Disaccharide synthetic lipid compounds and uses thereof
PCT/US2013/036425 WO2013155448A1 (en) 2012-04-12 2013-04-12 Disaccharide synthetic lipid compounds and uses thereof

Publications (1)

Publication Number Publication Date
IN2014DN09392A true IN2014DN09392A (en) 2015-07-17

Family

ID=49325307

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9392DEN2014 IN2014DN09392A (en) 2012-04-12 2013-04-12

Country Status (9)

Country Link
US (2) US9241988B2 (en)
EP (2) EP2836499B1 (en)
JP (3) JP6271510B2 (en)
CN (2) CN104470938B (en)
CA (1) CA2870008C (en)
ES (1) ES2787876T3 (en)
HK (1) HK1207383A1 (en)
IN (1) IN2014DN09392A (en)
WO (1) WO2013155448A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2486938T3 (en) 2006-09-26 2018-08-31 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US9241988B2 (en) * 2012-04-12 2016-01-26 Avanti Polar Lipids, Inc. Disaccharide synthetic lipid compounds and uses thereof
PL2850431T3 (en) 2012-05-16 2018-09-28 Immune Design Corp. Vaccines for hsv-2
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9017698B2 (en) 2013-09-25 2015-04-28 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
RU2694367C2 (en) * 2014-09-12 2019-07-12 Бестевил Холдинг Б.В. Methods of producing adjuvanted virosome and adjuvanted virosomes, obtained by said methods
CN107405395A (en) * 2015-03-17 2017-11-28 红杉科学有限公司 The method of the composition and treatment urinary tract infections of vaccine and adjuvant
EP3849521A1 (en) 2018-09-14 2021-07-21 Massachusetts Institute Of Technology Nanoparticle vaccine adjuvant and methods of use thereof
US20220339282A1 (en) 2018-11-29 2022-10-27 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
BR112022008761A2 (en) 2019-11-22 2022-07-26 Glaxosmithkline Biologicals Sa DOSAGE AND ADMINISTRATION OF A SACCHARIDE GLYCOCONJUGATE VACCINE
WO2023114570A1 (en) 2021-12-19 2023-06-22 Massachusetts Institute Of Technology Compositions and methods for long-lasting germinal center responses to a priming immunization
WO2024064783A1 (en) 2022-09-21 2024-03-28 Wisconsin Alumni Research Foundation Compositions and methods to enhance therapeutic efficacy of cancer therapies

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066794A (en) 1984-08-24 1991-11-19 Daiichi Pharmaceutical Co., Ltd. Process for preparing a disaccharide derivative
GR860379B (en) * 1985-02-22 1986-06-11 Akzo Nv Novel disaccharide and trisaccharide derivatives of the lipid a type
JP2535048B2 (en) 1988-02-29 1996-09-18 第一製薬株式会社 Novel disaccharide derivative and its salt
JPH06206893A (en) * 1992-09-07 1994-07-26 Suntory Ltd New disaccharide derivative
WO1995007285A1 (en) 1993-09-07 1995-03-16 Suntory Limited Novel disaccharide derivative
SK281944B6 (en) * 1993-11-17 2001-09-11 Laboratoires Om S. A. Beta(1->6)glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
JPH10152497A (en) * 1996-09-30 1998-06-09 Otsuka Pharmaceut Factory Inc Helicobacter pylori lipid a
NZ508013A (en) * 1998-05-07 2003-08-29 Corixa Corp Adjuvant composition for use with an antigen in a vaccine composition
CN1247262C (en) 1998-07-14 2006-03-29 惠氏控股有限公司 Adjuvant and vaccine composition containing monophosphoryl lipid A
US20020022032A1 (en) * 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
ES2370262T3 (en) * 1999-11-15 2011-12-14 Oncothyreon Inc. LIPID ANALOGS TO SYNTHETICS AND THEIR USES.
CN1907289A (en) * 2000-05-19 2007-02-07 科里克萨有限公司 Prophylactic and therapeutic treatment of infectious and other diseases with mono and disaccharide-based compounds
ES2305086T3 (en) * 2000-05-19 2008-11-01 Corixa Corporation PROFILACTIC AND THERAPEUTIC TREATMENT OF ALLERGIC, AUTOIMMUNE AND INFECTIOUS DISEASES WITH COMPOUNDS BASED ON MONOSACARIDS.
US20030031684A1 (en) * 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
GB0420634D0 (en) * 2004-09-16 2004-10-20 Glaxosmithkline Biolog Sa Vaccines
US7622128B2 (en) * 2005-12-13 2009-11-24 University Of Washington Porphyromonas gingivalis 1435/1449 LPS as an immune modulator
WO2008059307A2 (en) * 2006-11-16 2008-05-22 Om Pharma Functionalized beta 1,6 glucosamine disaccharides and process for their preparation
CA2698668A1 (en) * 2007-09-07 2009-03-19 University Of Georgia Research Foundation, Inc. Synthetic lipid a derivative
EP3508505A1 (en) * 2007-12-24 2019-07-10 ID Biomedical Corporation of Quebec Recombinant rsv antigens
US9241988B2 (en) * 2012-04-12 2016-01-26 Avanti Polar Lipids, Inc. Disaccharide synthetic lipid compounds and uses thereof

Also Published As

Publication number Publication date
EP2836499A4 (en) 2015-11-25
CN107412766A (en) 2017-12-01
HK1207383A1 (en) 2016-01-29
JP6764396B2 (en) 2020-09-30
US10143744B2 (en) 2018-12-04
CN104470938A (en) 2015-03-25
US20130273149A1 (en) 2013-10-17
ES2787876T3 (en) 2020-10-19
US20160136271A1 (en) 2016-05-19
CA2870008C (en) 2021-05-04
JP6271510B2 (en) 2018-01-31
EP3674309A1 (en) 2020-07-01
WO2013155448A1 (en) 2013-10-17
CN104470938B (en) 2017-07-28
US9241988B2 (en) 2016-01-26
JP2020147579A (en) 2020-09-17
JP7189906B2 (en) 2022-12-14
CA2870008A1 (en) 2013-10-17
JP2018070652A (en) 2018-05-10
EP2836499B1 (en) 2020-02-26
EP2836499A1 (en) 2015-02-18
JP2015512946A (en) 2015-04-30

Similar Documents

Publication Publication Date Title
IN2014DN09392A (en)
EP3551201A4 (en) Methods and compositions relating to isolated and purified microbes
PH12016501151A1 (en) Nrf2 regulators
MX2016004927A (en) Compositions useful for treating disorders related to kit.
PH12015502401A1 (en) Compositions and methods for enhancing microbial stability
PH12015502216A1 (en) Compositions and methods for improving the health of aquatic animals
PH12014502350A1 (en) Mixtures, methods and compositions pertaining to conductive materials
EP3725811A3 (en) Compositions for inhibiting masp-2 dependent complement activation
EA201290876A1 (en) COMPOSITIONS OF INDUCED DENDRITIC CELLS AND THEIR USE
MX2015005944A (en) Microbial strains, compositions, and methods for increasing available phosphate for plants.
GB0917002D0 (en) Improved shigella blebs
MX2016011898A (en) Compositions of selenoorganic compounds and methods of use thereof.
IN2014DN08721A (en)
AU2015287674B2 (en) Topical antiviral compositions and methods of using the same
IN2014DN08481A (en)
PH12014502840B1 (en) Vaccine compositions
MY190647A (en) Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
MX2018011162A (en) Methods of purifying collagen 7.
MX2017008423A (en) Transdermal formulations.
MX348325B (en) Galacto-oligosaccharide-containing composition and a method of producing it.
IN2014DN06104A (en)
IN2014DN08412A (en)
SG10201900541QA (en) Derivatives of xanthone compounds
IN2013MU03641A (en)
MX2016000313A (en) Novel light stabilizers.